Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Alexander Fedenko"'
Autor:
Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various
Externí odkaz:
https://doaj.org/article/15215176b97f49e896e659eee237e11e
Publikováno v:
Rare Tumors, Vol 14 (2022)
Ewing sarcoma is a primitive neuroectodermal tumor which seldom presents with primary disease in people over age 40 and outside of the appendicular or axial skeleton. We examine a case of primary thoracic Ewing Sarcoma diagnosed initially by CT-guide
Externí odkaz:
https://doaj.org/article/1ba0ad26c20b437d88492900fc61348d
Autor:
Anna M. Frezza, Vinod Ravi, Salvatore Lo Vullo, Bruno Vincenzi, Francesco Tolomeo, Tom Wei‐Wu Chen, Pawel Teterycz, Giacomo G. Baldi, Antoine Italiano, Nicolas Penel, Antonella Brunello, Florance Duffaud, Nadia Hindi, Shintaro Iwata, Alannah Smrke, Alexander Fedenko, Hans Gelderblom, Winette Van Der Graaf, Aurore Vozy, Elizabeth Connolly, Massimiliano Grassi, Robert S. Benjamin, Javier‐Martin Broto, Giovanni Grignani, Robin L. Jones, Akira Kawai, Andrzej Tysarowski, Luigi Mariani, Paolo G. Casali, Silvia Stacchiotti
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2645-2659 (2021)
Abstract Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra‐rare sarcoma, marked by WWTR1‐CAMTA1 or YAP1‐TFE3 fusions. Methods Twenty sa
Externí odkaz:
https://doaj.org/article/56e3c27fbb994c9fa4bc5bb179921864
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-087
Autor:
Anna Kornietskaya, Sevindzh Evdokimova, Andrei Kachmazov, Alexander. Fedenko, Larisa Bolotina, Dmitriy Sidorov, Nadezhda Volchenko, Natalia Goeva, Anastasia Govaleshko, Andrey Kaprin
Publikováno v:
Frontiers in Oncology. 12
Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare tumor, associated with favorable prognosis and long-term survival in patients with advanced disease. However, limited data exist on systemic therapy for such patients. Herein,
Autor:
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza
Background: Few prospective studies have compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or BRCA2-mutated ovarian carcinoma. We aimed to assess rucaparib versus platinum-base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7c8bd136530b0776d8ec0abe745697
http://hdl.handle.net/10807/198484
http://hdl.handle.net/10807/198484
Autor:
Antoine Italiano, Giovanni Grignani, Luigi Mariani, Paolo G. Casali, Robin L. Jones, Massimiliano Grassi, Akira Kawai, Nicolas Penel, Aurore Vozy, Antonella Brunello, Salvatore Lo Vullo, Paweł Teterycz, Florance Duffaud, Tom Wei-Wu Chen, Francesco Tolomeo, Robert S. Benjamin, Giacomo Giulio Baldi, Andrzej Tysarowski, Bruno Vincenzi, Shintaro Iwata, Alannah Smrke, Nadia Hindi, Hans Gelderblom, Winette T. A. van der Graaf, Anna Maria Frezza, Elizabeth Connolly, Javier‐Martin Broto, Silvia Stacchiotti, Vinod Ravi, Alexander Fedenko
Publikováno v:
Cancer Medicine, 10(8), 2645-2659. WILEY
Cancer Medicine, 10, 8, pp. 2645-2659
Cancer Medicine
Cancer Medicine, 10, 2645-2659
Cancer Medicine, Vol 10, Iss 8, Pp 2645-2659 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancer Medicine, 10, 8, pp. 2645-2659
Cancer Medicine
Cancer Medicine, 10, 2645-2659
Cancer Medicine, Vol 10, Iss 8, Pp 2645-2659 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
[Background] This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.
[Methods] Twenty sarcoma
[Methods] Twenty sarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26593386408c206f394c8abf875a51c5
https://hdl.handle.net/1887/3276579
https://hdl.handle.net/1887/3276579
Autor:
David Cibula, Francesco Raspagliesi, Sandra Goble, Igor Bondarenko, Giovanni Scambia, Yaroslav Shparyk, Nicoletta Colombo, Róbert Póka, Valentyn Svintsitskiy, Ana Oaknin, Alla Lisyanskaya, Mikhail Dvorkin, R Kristeleit, Tamar Safra, Irina Rakhmatullina, Andreia Cristina de Melo, Ling Ma, Amit M. Oza, Luciano Biela, Marina Nechaeva, Beata Mackowiak-Matejczyk, Kevin K. Lin, Daleen Thomas, Karen Mclachlan, Alexander Fedenko
Publikováno v:
Gynecologic Oncology. 162:S3-S4
Objectives: Prospective studies comparing poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors with standard-of-care (SOC) chemotherapy (CT) in patients (pts) with relapsed ovarian cancer (OC) are currently limited. ARIEL4 (NCT02855944) is
Publikováno v:
Clinical imaging. 69
Bizarre parosteal osteochondromatous proliferation (BPOP) or Nora's lesion, is a rare benign surface-based bone lesion most commonly involving the tubular bones of hands and feet. We report an unusual case of BPOP affecting the distal ulna in a 22-ye
Autor:
Akira Kawai, Brian A. Van Tine, Javier Martin-Broto, Andrew J. Wagner, Albiruni Ryan Abdul Razak, Se Hoon Park, Yoichi Naito, Robin L. Jones, Patrick Schöffski, Jennifer Wright, William D. Tap, Chueh Chuan Yen, Victoria Soldatenkova, Axel Le Cesne, Ashwin Shahir, Gary Mo, Alexander I. Spira, Zsuzsanna Papai, Anders Krarup-Hansen, Kristen N. Ganjoo, Alexander Fedenko
Publikováno v:
JAMA
IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxo